What the FDA labels say about taking them together
Dasatinib and dexlansoprazole
Dexlansoprazole's FDA label of February 17, 2025 names dasatinib in its drug interactions section; dasatinib's label does not name dexlansoprazole itself but warns about its class (Proton pump inhibitors (PPIs)). The dexlansoprazole label: “Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.”
Check it at the source: the dasatinib FDA label on DailyMed (effective November 12, 2025, Alembic Pharmaceuticals Limited); the dexlansoprazole FDA label on DailyMed (effective February 17, 2025, Takeda Pharmaceuticals America, Inc.).
What does the dasatinib label say about dexlansoprazole?
Dasatinib's label does not name dexlansoprazole itself; it warns about its class (Proton pump inhibitors (PPIs)):
Dasatinib label, drug interactionsDo not administer H 2 antagonists or proton pump inhibitors with dasatinib.
Dasatinib label, drug interactionsDo not administer H 2 antagonists or proton pump inhibitors with dasatinib. Consider the use of antacids in place of H 2 antagonists or proton pump inhibitors.
Source: FDA drug label (DASATINIB), Alembic Pharmaceuticals Limited, effective November 12, 2025 (SPL set 645fcf26-1b2f-40c5-881b-8effe02defbd), via openFDA; the full label on DailyMed
What does the dexlansoprazole label say about dasatinib?
Dexlansoprazole label, drug interactionsClinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Mycophenolate mofetil (MMF): Coadministration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. …
Source: FDA drug label (Dexilant), Takeda Pharmaceuticals America, Inc., effective February 17, 2025 (SPL set 9819f033-3bbe-442e-8e92-45fec77b237d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dasatinib | Dexlansoprazole | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Acid reflux and ulcers |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $26.46 per tablet 100 mg tablet | $3.71 per capsule 60 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once